Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721954 | 0.79 | SLC6A2 (0.55) | SLC18A3SIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL633352 | 0.79 | SLC6A2 (0.55) | SLC18A3SIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL633351 | 0.79 | SLC6A2 (0.55) | SLC18A3SIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL25803074 | 0.74 | OPRM1 (0.58) | SLC18A3SIGMAR1OPRM1OPRL1 | |
| SCHEMBL14081578 | 0.73 | CHRM1 (0.56) | SLC18A3SIGMAR1 | |
| SCHEMBL2887259 | 0.72 | — | — | |
| SCHEMBL18711267 | 0.71 | SLC18A3 (0.50) | SLC18A3SIGMAR1DRD2HTR1ADRD4 | |
| SCHEMBL14388279 | 0.71 | ACHE (0.49) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL23124105 | 0.70 | SLC18A3 (0.53) | SLC18A3SIGMAR1DRD2HTR1ADRD4 | |
| Ethybenztropine SCHEMBL250681 | 0.70 | DRD2 (0.72) | SIGMAR1MEN1KMT2ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2009062676-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | SLC18A3 1141/4885SIGMAR1 361/4885MEN1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.